Stunningly, some of the most dramatic gains in cancer survival rates have occurred among patients with certain cancer types, such as metastatic non–small cell lung cancer (NSCLC), for which survival outcomes were poor historically. At this time, however, our abilities to effectively deliver these extraordinary advances are challenged by the rapidly escalating costs of care, continued disparities in cancer survival outcomes, and care payment and deliver systems that erect barriers for patients and families trying to access the care they need.
Rising costs are a significant challenge to the financial sustainability of health care payers, including state and local governments, private health plans, and employers. One major success story in cancer care has been the rapid pace of development of novel, innovative anticancer therapeutics and immuno-oncological agents. Authors of the IQVIA…